Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies

Targeted kinase inhibitors and camptothecins have shown preclinical and clinical activity in several cancers. This trial evaluated the maximum tolerated dose (MTD) and dose‐limiting toxicities of sorafenib and topotecan administered orally in pediatric patients with relapsed solid tumors. Sorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Reed, Damon R., Mascarenhas, Leo, Manning, Kathleen, Hale, Gregory A., Goldberg, John, Gill, Jonathan, Sandler, Eric, Isakoff, Michael S., Smith, Tiffany, Caracciolo, Jamie, Lush, Richard M., Juan, Tzu‐Hua, Lee, Jae K., Neuger, Anthony M., Sullivan, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735769/
https://www.ncbi.nlm.nih.gov/pubmed/26714427
http://dx.doi.org/10.1002/cam4.598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735769/
https://www.ncbi.nlm.nih.gov/pubmed/26714427
http://dx.doi.org/10.1002/cam4.598

Ejemplares similares